Tumores Mamários
Trastuzumabe para câncer de mama em estágio inicial e HER-2-positivo: uma metanálise de 13.864 mulheres em 7 estudos randomizados.
15 Out, 2021 | 16:18h
Comentário no Twitter
@OncoAlert Success of a monoclonal antibody when @ right target – 10 yr benefits of trastuzumab – #EBCTCG meta-analysis (N>13,000):
👉Impressive absolute and relative ~1/3 reduced deaths, ~1/3 recurrences
👉ER-: Recur⬇️ 11%
👉ER+: Recur⬇️ 8%@kevinpunie @prat_aleix @itsnot_pink https://t.co/O1WKcEEuGG— Nicole Kuderer (@NicoleKuderer) August 4, 2021
Estudo de coorte | Mulheres tratadas com radioterapia para câncer de mama do lado esquerdo tiveram mais que o dobro de risco de doença arterial coronariana em comparação com mulheres que receberam o mesmo tratamento, mas para o lado direito.
1 Out, 2021 | 21:55hComentários:
CAD in Young Women After Radiation Therapy for Breast Cancer – American College of Cardiology
Comentário no Twitter
According to a study from #JACCCardioOnc, women with left-sided breast cancer undergoing radiation therapy between 1985 and 2008 had over twice the risk of subsequent #cvCAD compared to women with right-sided breast cancer. Learn more here: https://t.co/5q9tToSSRp #CardioOnc
— American College of Cardiology (@ACCinTouch) September 22, 2021
Revisão sistemática | Radiação mamária parcial vs. radioterapia mamária total para câncer de mama precoce.
17 Set, 2021 | 11:50h
Comentário no Twitter
For women with early-stage #BreastCancer, how does giving radiotherapy to part of the breast compare with giving #radiotherapy to the whole breast? The latest Cochrane Review from @CochraneBCancer brings together nine studies, which involved 15,187 women: https://t.co/fVuSrSDAZM pic.twitter.com/QOufZYSH5I
— Cochrane UK (@CochraneUK) September 3, 2021
Relatório de longo prazo de estudo avaliando o uso da radiação após cirurgia excisional de carcinoma ductal in situ de baixo risco.
14 Set, 2021 | 14:11h
Comentário no Twitter
At 15 years, NRG-RTOG 9804 "good risk" breast #DCIS trial shows advantage of radiation therapy over observation to reduce #breastcancer risk https://t.co/l5OWVOb5Dg
#JCO #BCSM #radonc @NRGOnc; @MSK_RadOnc pic.twitter.com/TPAZRheoHT— ASCO Publications (@ASCO_pubs) September 10, 2021
Revisão | Terapia endócrina neoadjuvante na prática clínica.
12 Set, 2021 | 21:58hNeoadjuvant Endocrine Therapy in Clinical Practice: A Review – JAMA Oncology (gratuito por tempo limitado)
Revisão sistemática mostra evidência insuficiente de que a inteligência artificial (IA) no rastreamento do câncer de mama seja precisa o bastante para substituir o escrutínio humano.
12 Set, 2021 | 21:39hEstudo original: Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy – The BMJ
Comentário no Twitter
A systematic review of #AI for mammography is very disappointing
"Thirty four (94%) of 36 AI systems evaluated in these studies were less accurate than a single radiologist, and all were less accurate than consensus of two or more radiologists"https://t.co/zqFTxojU9J @bmj_latest pic.twitter.com/wylwOsf4ua— Eric Topol (@EricTopol) September 2, 2021
Estudo de coorte | Uso de contraceptivo oral e risco de câncer ovariano para portadoras de mutações nos genes BRCA1/2.
20 Ago, 2021 | 12:02h
Comentário no Twitter
For #BRCA1 mutation carriers, longer duration of oral contraceptive use (>10 yr) is associated with a greater reduction in #OvarianCancer risk, and the protection is long term. https://t.co/HrrutgaYKX
— Anna Chichura, MD (@AnnaChichuraMD) July 3, 2021
Cirurgia oncoplástica de mama: um guia para boas práticas.
19 Ago, 2021 | 12:03hOncoplastic breast surgery: A guide to good practice – European Journal of Surgical Oncology